摘要:
Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.
摘要:
A new antitumor antibiotic designated herein as BU-3862T is produced by fermentation of Streptomyces hygroscopicus ATCC 53709. BU-3862T and its diacetyl and dihydro derivatives inhibit the growth of tumors in experimental animals.
摘要:
The present invention relates to a novel .alpha.-glucosidase inhibitor, pradimicin Q, having the following formula ##STR1## and its pharmaceutically acceptable base salts.
摘要:
Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
摘要:
A new antibiotic having the chromophore structure of the plurmycin family of antibiotics is produced by fermentation of Streptomyces violaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.
摘要:
An new antibiotic having the chromophore structure of the pluramycin family of antibiotics is produced by fermentation of Streptomyces violaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.
摘要:
Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.
摘要:
Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.
摘要:
Disclosed are novel anthracyclinone glycosides represented by the chemical formula ##STR1## wherein R.sup.1 is hydrogen or methyl;R.sup.2 is hydrogen or hydroxyl;R.sup.3 is hydrogen or methoxycarbonyl;R.sup.4 is two hydrogen atoms or an oxygen atom;R.sup.5 is hydrogen, hydroxyl or --OCOX (wherein X is lower alkyl or aralkyl);R.sup.6 is amino, monomethylamino or dimethylamino;R.sup.7 is hydrogen or acetyl; andR.sup.8 is hydrogen or L-cinerulose A ##STR2## but, when R.sup.1 and R.sup.3 are hydrogen and methoxycarbonyl respectively, R.sup.2 is hydrogen; R.sup.4 is two hydrogen atoms; R.sup.5 is hydrogen; R.sup.6 is amino, monoethylamino or dimethylamino; R.sup.7 is acetyl; and R.sup.8 is L-cinerulose A,and their acid addition salts and a method for preparation thereof which consists of treating O-alpha-L-cinerulosyl-(1.fwdarw.4)-O-(3-O-acetyl-2-deoxy-alpha-L-fucosyl)-(1.fwdarw.4)-alpha-L-rhodosamine with corresponding aglycones.
摘要:
New anthracycline compounds, 2-hydroxy-aclacinomycins M, N, S and T having potent antitumor activity and low toxicity, and the processes for the preparation thereof from 2-hydroxy-aclacinomycin A by reduction or acid hydrolysis are disclosed.